BDTX · Insider Trading
Black Diamond Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by BDTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Ali Behbahani | Director | A | +7,707 | +$14.87K |
| 2026-09-21 | Prakash Raman | Director | A | +6,801 | +$13.13K |
| 2026-06-29 | Shannon Campbell | Director | A | +40,000 deriv. | — |
| 2026-06-29 | Garry E Menzel | Director | A | +40,000 deriv. | — |
| 2026-06-29 | Kapil Dhingra | Director | A | +40,000 deriv. | — |
| 2026-06-29 | Ali Behbahani | Director | A | +40,000 deriv. | — |
| 2026-06-29 | Prakash Raman | Director | A | +40,000 deriv. | — |
| 2026-06-29 | Samarth Kulkarni | Director | A | +40,000 deriv. | — |
| 2026-06-22 | Prakash Raman | Director | A | +7,907 | +$13.13K |
| 2026-06-22 | Ali Behbahani | Director | A | +8,961 | +$14.88K |
| 2026-03-20 | Prakash Raman | Director | A | +6,105 | +$13.13K |
| 2026-03-20 | Ali Behbahani | Director | A | +6,919 | +$14.88K |
| 2026-01-23 | Mark A. Velleca | PRESIDENT & CEO | A | +600,000 deriv. | — |
| 2026-01-23 | Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | A | +250,000 deriv. | — |
| 2026-01-23 | Erika Jones | SEE REMARKS | A | +200,000 deriv. | — |
| 2026-01-23 | Sergey Yurasov | CHIEF MEDICAL OFFICER | A | +250,000 deriv. | — |
| 2026-01-23 | Brent Hatzis-Schoch | SEE REMARKS | A | +250,000 deriv. | — |
| 2025-12-15 | Prakash Raman | Director | A | +4,665 | +$12.88K |
| 2025-12-15 | Ali Behbahani | Director | A | +5,208 | +$14.37K |
| 2025-09-22 | Prakash Raman | Director | A | +3,843 | +$12.87K |
| 2025-09-22 | Ali Behbahani | Director | A | +4,291 | +$14.37K |
| 2025-06-20 | Ali Behbahani | Director | A | +6,170 | +$14.38K |
| 2025-06-20 | Prakash Raman | Director | A | +5,526 | +$12.88K |
| 2025-06-12 | Ali Behbahani | Director | A | +30,550 deriv. | — |
| 2025-06-12 | Garry E Menzel | Director | A | +30,550 deriv. | — |
| 2025-06-12 | Shannon Campbell | Director | A | +30,550 deriv. | — |
| 2025-06-12 | Kapil Dhingra | Director | A | +30,550 deriv. | — |
| 2025-06-12 | Prakash Raman | Director | A | +30,550 deriv. | — |
| 2025-06-12 | Samarth Kulkarni | Director | A | +30,550 deriv. | — |
| 2025-03-21 | Prakash Raman | Director | A | +6,848 | +$12.87K |
| 2025-03-21 | Ali Behbahani | Director | A | +7,646 | +$14.37K |
| 2025-03-20 | BB BIOTECH AG | 10%+ Owner | Sell | −5,784,292 | −$12.00M |
| 2025-01-31 | Mark A. Velleca | PRESIDENT & CEO | A | +75,000 | — |
| 2025-01-31 | Sergey Yurasov | CHIEF MEDICAL OFFICER | A | +75,000 | — |
| 2025-01-31 | Brent Hatzis-Schoch | SEE REMARKS | A | +75,000 | — |
| 2025-01-31 | Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | A | +75,000 | — |
| 2025-01-31 | Erika Jones | SEE REMARKS | A | +75,000 | — |
| 2024-12-16 | Prakash Raman | Director | A | +5,150 | +$12.88K |
| 2024-12-16 | Shannon Campbell | Director | A | +4,500 | +$11.25K |
| 2024-12-16 | Ali Behbahani | Director | A | +5,750 | +$14.38K |
| 2024-09-20 | Prakash Raman | Director | A | +2,694 | +$12.88K |
| 2024-09-20 | Shannon Campbell | Director | A | +2,354 | +$11.25K |
| 2024-09-20 | Ali Behbahani | Director | A | +3,007 | +$14.37K |
| 2024-08-30 | Versant Vantage I, L.P. | 10%+ Owner | Sell | −221,600 | −$1.40M |
| 2024-06-21 | Shannon Campbell | Director | A | +2,011 | +$10.01K |
| 2024-06-21 | Ali Behbahani | Director | A | +2,887 | +$14.38K |
| 2024-06-21 | Prakash Raman | Director | A | +2,301 | +$11.46K |
| 2024-06-06 | Ali Behbahani | Director | A | +30,550 deriv. | — |
| 2024-06-06 | Kapil Dhingra | Director | A | +30,550 deriv. | — |
| 2024-06-06 | Prakash Raman | Director | A | +30,550 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ali Behbahani | Director | 4,558,993 | $7.31M |
| BB BIOTECH AG | 10%+ Owner | 3,233,547 | $5.19M |
| Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | 170,192 | $272.99K |
| Mark A. Velleca | PRESIDENT & CEO | 121,522 | $194.92K |
| Erika Jones | SEE REMARKS | 85,150 | $136.58K |
| Brent Hatzis-Schoch | SEE REMARKS | 83,400 | $133.77K |
| Sergey Yurasov | CHIEF MEDICAL OFFICER | 75,000 | $120.30K |
| Prakash Raman | Director | 51,840 | $83.15K |
| Garry E Menzel | Director | 51,825 | $83.13K |
| Shannon Campbell | Director | 8,865 | $14.22K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BDTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.